Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Completed Phase 3 Interventional

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

ClinicalTrials.gov ID: NCT00099502

Public ClinicalTrials.gov record NCT00099502. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine * whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms * whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg

Study identification

NCT ID
NCT00099502
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bayer
Industry
Enrollment
2,244 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2003 (Type not available)
Primary completion
Not listed
Completion
Aug 2007 (Actual)
Last update posted
Dec 19, 2008

2003 – 2007

United States locations

U.S. sites
57
U.S. states
33
U.S. cities
55
Facility City State ZIP Site status
Not listed Birmingham Alabama 35294 —
Not listed Cullman Alabama 35058 —
Not listed Phoenix Arizona 85013 —
Not listed Tucson Arizona 85741-3537 —
Not listed Berkeley California 94705 —
Not listed La Jolla California 92037 —
Not listed Sacramento California 95817 —
Not listed San Francisco California 94117 —
Not listed Englewood Colorado 80110 —
Not listed Fort Collins Colorado 80528 —
Not listed Wilmington Delaware 19806 —
Not listed Washington D.C. District of Columbia 20037 —
Not listed Miami Florida 33125 —
Not listed Tampa Florida 33606-3508 —
Not listed Tampa Florida 33609 —
Not listed Atlanta Georgia 30309-1465 —
Not listed Augusta Georgia 30912 —
Not listed Chicago Illinois 60637-1470 —
Not listed Fort Wayne Indiana 46805 —
Not listed Indianapolis Indiana 46202 —
Not listed Des Moines Iowa 50314 —
Not listed Kansas City Kansas 66160 —
Not listed Lexington Kentucky 40536 —
Not listed Louisville Kentucky 40202 —
Not listed Shreveport Louisiana 71130 —
Not listed Detroit Michigan 48202 —
Not listed Duluth Minnesota 55805-1984 —
Not listed St Louis Missouri 63110 —
Not listed Henderson Nevada 89052 —
Not listed Reno Nevada 89557-0035 —
Not listed Lebanon New Hampshire 03756-0001 —
Not listed New Brunswick New Jersey 08901 —
Not listed Albuquerque New Mexico 87131 —
Not listed Albany New York 12208 —
Not listed Mineola New York 11501-3987 —
Not listed Rochester New York 14642 —
Not listed Stony Brook New York 11794 —
Not listed Charlotte North Carolina 28203 —
Not listed Durham North Carolina 27710 —
Not listed High Point North Carolina 27262 —
Not listed Winston-Salem North Carolina 27157-1009 —
Not listed Cincinnati Ohio 45219 —
Not listed Columbus Ohio 43210-1240 —
Not listed Tualatin Oregon 97062 —
Not listed Philadelphia Pennsylvania 19104 —
Not listed Philadelphia Pennsylvania 19107 —
Not listed Pittsburgh Pennsylvania 15213-2592 —
Not listed Providence Rhode Island 02905 —
Not listed Charleston South Carolina 29425 —
Not listed Nashville Tennessee 37205 —
Not listed Houston Texas 77030 —
Not listed San Antonio Texas 78229 —
Not listed Fairfax Virginia 22031 —
Not listed Seattle Washington 98101 —
Not listed Tacoma Washington 98405 —
Not listed Marshfield Wisconsin 54449 —
Not listed Milwaukee Wisconsin 53215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 142 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00099502, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 19, 2008 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00099502 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →